Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18376980 | 0.87 | PYGB (0.57) | PYGBGAACA12CA1CA2 | |
| SCHEMBL18376977 | 0.86 | PYGB (0.56) | PYGBGAACA12CA1CA2 | |
| SCHEMBL14342166 | 0.85 | PYGB (0.61) | PYGBGAACA12CA1CA2 | |
| SCHEMBL18376253 | 0.84 | PYGB (0.60) | PYGBGAACA12CA1CA2 | |
| SCHEMBL25496536 | 0.83 | PYGB (0.63) | PYGBGAACA12CA1CA2 | |
| SCHEMBL12430289 | 0.81 | PYGB (0.64) | PYGBGAACA12CA1CA2 | |
| SCHEMBL14342150 | 0.81 | PYGB (0.61) | PYGBGAACA12CA1CA2 | |
| SCHEMBL18376575 | 0.80 | PYGB (0.55) | PYGBGAACA12CA1CA2 | |
| SCHEMBL18376576 | 0.79 | PYGB (0.56) | PYGBGAACA12CA1CA2 | |
| SCHEMBL5022897 | 0.77 | PYGB (0.57) | PYGBGAACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170007709-A1 | GLYCOAMINO ACID AND USE THEREOF | AJINOMOTO CO., INC. (JP) | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170007709-A1 | GLYCOAMINO ACID AND USE THEREOF | SLC6A15, NGLY1, SLC7A1 | PYGB 543/4885GAA 177/4885CA12 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.